Compositions and methods for treating cytokine storm

Reducing inflammatory cytokine levels through peptides of Reg3α active center analogues solves the shortcomings of reducing proinflammatory cytokines and treating cytokine storms in the prior art, significantly alleviating the inflammatory response, and improving the prognosis of COVID-19 and related diseases.

CN118922432APending Publication Date: 2024-11-08SHENZHEN HIGHTIDE BIOPHARM
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380017618.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-01-25
Filing Date
2023-01-20
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art has shortcomings in reducing proinflammatory cytokines and treating cytokine storms, especially in viral infections such as COVID-19-related diseases, where existing treatments are ineffective and have unmet safety and effectiveness.

Method used

Using peptides with Reg3α active center analogues to reduce the infiltration of neutrophils and macrophages significantly reduce damage, prevent or reduce concurrency by reducing the levels of inflammatory cytokines such as TNF-α, IL-6 and IL-1β. , promote recovery.

Benefits of technology

Significantly reduce the severity of the inflammatory response, improve patients' resistance to organ and tissue damage, improve disease prognosis, and is suitable for the treatment of COVID-19, COVID sequelae and other inflammatory diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118922432A_ABST
    Figure CN118922432A_ABST
Patent Text Reader

Abstract

The present invention provides compositions and methods for treating, ameliorating, or preventing cytokine storms associated with viral infections (e.g., caused by SARS-CoV-2), drug therapy or therapy, traumatic or inflammatory diseases, or related diseases and conditions.
Need to check novelty before this filing date? Find Prior Art

Description

Priority claims and related patent applications

[0001] This application claims priority to U.S. Provisional Application Serial No. 63 / 302,878, filed on January 25, 2022, the entire contents of which are incorporated herein by reference. Technical Field

[0002] The present invention generally relates to drugs and their therapeutic uses. More specifically, the present invention provides compositions and methods for reducing proinflammatory cytokines and treating cytokine storms associated with viral infections (e.g., SARS-CoV-2 or COVID-19) and related diseases and conditions. Background Art

[0003] COVID-19 is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The SARS-CoV-2 virus can be passed from an infected person’s mouth or nose in the form of small liquid particles when they cough, sneeze, talk, or breathe. These particles range from larger respiratory droplets to smaller aerosols. The viral surface spike protein mediates the entry of SARS-CoV-2 into human cells.

[0004] Symptoms of COVID-19 vary, but generally include fever, cough, fatigue, difficulty breathing, and loss of smell and taste. While most people have mild symptoms, a significant number of people develop acute respiratory distress syndrome (ARDS). ARDS can be caused by cytokine storms, multiple organ failure, septic shock, and blood clots. Long-term damage to organs, especially the lungs and heart, has been frequently observed. (See, e.g., Ye et al., The Journal of Infection, Vol. 80, No. 6, pp. 607-613, Brevini, T., Maes, M., and Webb, GJ et al., Nature, 2022)

[0005] Although COVID-19 patients may experience mild symptoms early in the course of the disease, these symptoms can suddenly worsen in the later stages of the disease. One possible reason is the inflammatory storm that is frequently triggered in the later stages. This inflammatory storm can lead to the failure of various organ functions, and some patients die due to non-pulmonary multi-organ failure. (Li et al., 2020, Journal of Pharmaceutical Analysis, Vol. 10, No. 2: pp. 102-108)

[0006] There is growing clinical evidence that some patients suffer long-term effects from their infection, known as post-COVID sequelae (aka post-acute COVID-19, long COVID, or chronic COVID, etc.). These patients experience recurring or persistent health problems long after being infected with COVID-19 (e.g., weeks, months, or years). It is reported that between one month and one year after being infected with COVID-19, 1 in 5 people aged 18 to 64 years have at least one medical condition that may be caused by COVID-19 infection. (See, e.g., Perlis et al., 2022, JAMA Netw Open, Vol. 5, No. 10; Household Pulse Survey, National Center for Health Statistics, 2022, https: / / www.cdc.gov / nchs / covid19 / pulse / long-covid.htm ; Levine et al., “Long COVID Research, Services, and Supports: A Call to Action,” August 2, 2022, Health Affairs Forefront 10.1377 / forefront.20220801.50344.)

[0007] Symptoms of post-COVID sequelae are wide-ranging and include fatigue, fever, respiratory and cardiac symptoms (e.g., difficulty thinking or concentrating, sometimes called “brain fog”), headaches, sleep problems, dizziness, depression or anxiety, digestive symptoms (e.g., diarrhea, stomach pain), joint or muscle pain, rash, etc. (see, e.g., Cassar et al., 2021, EClinicalMedicine, Vol. 41, 101159; Singh et al., 2020, Am J Physiol Cell Physiol, Vol. 319: pp. C258-C267; Ajaz et al., 2020, Am J Physiol Cell Physiol, Vol. 320: pp. C57-C65, 2021; Gibellini et al., 2020, EMBO Molecular Medicine, Vol. 12: e13001; Raman et al., 2022, Euro. Heart J., Vol. 43, pp. 1157-1172; Evans et al., 2022, Lancet Respir. Med., Vol. 10: pp. 761-775; Singh et al., 2022, Chest, Vol. 161, No. 1: pp. 54-63; Shields et al., 2022, Clin. and Exper. Immun., Vol. 209, No. 3: pp. 247-258; Pretorius et al., 2021, Cardio Diabetology, Vol. 20, No. 172)

[0008] The term "cytokine storm" was first described in the medical literature in 1993 and is a severe systemic inflammatory response triggered by various factors such as infection or certain drugs. Alegre et al. reported an experimental study in a model of hematological malignancies in 1991, in which a similar term "cytokine release syndrome" (CRS) was used. (Ferrara et al., 1993, Transplant Proc., Vol. 25 (1pt 2): pp. 1216-1217; Alegre et al., 1991, J Immunol., Vol. 146 No. 4: pp. 1184-1191) Since then, studies related to cytokine storms have been reported, which are related to different viral diseases, bacterial infections, hemophagocytic lymphohistiocytosis, multiple sclerosis, pancreatitis and other inflammatory diseases, which can cause cytokine storms and lead to multiple organ dysfunction syndrome (MODS). The organs most affected are usually the lungs, cardiovascular system and kidneys. (Karlsson et al., 2007, Intensive Care Med., Vol. 33, No. 3: pp. 435-443)

[0009] In a cytokine storm, after the body is infected with a virus or microorganism, and when the body's immune function is abnormal, inflammatory cytokines continue to be produced in large quantities, causing more immune cells to continue to be activated to gather at inflammatory sites. A variety of cytokines in body fluids (e.g., TNF-α, IL-1, IL-6, IL-12, IFN-α, IFN-β, IFN-γ, MCP-1, and IL-8) are rapidly produced in large quantities. (Huang et al., 2020, Lancet, Vol. 395, No. 10223: pp. 497-506) Excessive immune cells and a variety of inflammatory cytokines can cause tissue congestion, edema, fever, and damage, which are important causes of acute respiratory distress syndrome. They may also cause other secondary infections or even lead to systemic inflammatory response syndrome. It is reported that severe COVID-19 patients often show a significant increase in inflammatory cytokines such as IL-6, TNF-α, and IFN-γ, which are characteristic of cytokine storms. When immune cells attack the normal tissues of patients with severe COVID-19, a strong immune cytokine storm occurs in these patients. The cytokine storm poses a great challenge to the clinical care of patients with severe COVID-19 who face high mortality during multiple attacks.

[0010] Currently, the prevention and treatment of COVID-19 include vaccination, supportive therapy, symptomatic treatment, and antiviral therapy. Various antiviral drugs have been studied for COVID-19, some of which have shown efficacy and reduced mortality. In November 2020, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy bamlanivimab for the treatment of mild to moderate COVID-19, and also granted an EUA for the combined administration of casirivimab and imdevimab for the treatment of mild to moderate COVID-19. In December 2021, the antiviral drug PAXLOVID TM (nirmatrelvir; ritonavir, developed by Pfizer) and LAGEVRIO TM (molnupiravir, developed by Merck) has received emergency use authorization (EUA) in the United States.

[0011] Despite these encouraging progress, viral variants that are resistant to vaccines and / or treatments continue to emerge as the pandemic spreads to more vulnerable demographics, including immunocompromised patients and high-risk groups such as the elderly and others who do not respond well to vaccines or currently available treatments.

[0012] Therapeutic agents for antagonizing the function of inflammatory cytokines to reduce the production of inflammatory cytokines have been studied. The purpose of antagonizing the function of inflammatory cytokines and downregulating the inflammatory response can be achieved by using monoclonal antibodies against IL-1, TNF-α, IL-6, IL-8, etc. or their receptor antagonists. However, clinical trials have shown that such immunomodulatory therapies are not effective in treating inflammatory storms and cannot significantly reduce morbidity and mortality. Possible explanations may be multifaceted: (1) when antagonizing the harmful effects of cytokines, they also weaken their normal physiological functions; (2) cytokine storms are a complex combination of multiple inflammatory factors, making the effect of using a single immune agent not obvious; (3) cytokine receptors have different subtypes, and the functions of these subtypes may also be different; and (4) the risk of compensatory anti-inflammatory response syndrome is increased.

[0013] Currently available therapeutic agents and methods for reducing proinflammatory cytokines and treating cytokine storms remain inadequate. In particular, there is an urgent and unmet need for safe and effective treatments for cytokine storms associated with viral infections, such as those caused by COVID-19. Summary of the invention

[0014] The present invention is based in part on the surprising discovery that certain Reg3α analogs can be effectively used to reduce proinflammatory cytokines and / or treat, reduce or prevent cytokine storms, such as those associated with viral infection (e.g., caused by COVID-19), drug treatment or therapy (e.g., during CAR-T therapy), trauma or inflammatory disease.

[0015] As stress proteins secreted by the body during inflammatory responses, regenerative islet-derived (Reg) proteins can play a key role in the prognosis of certain diseases, such as preventing complications through anti-inflammatory, anti-apoptotic / necrotic and / or anti-bacterial effects, as well as promoting cell proliferation and tissue regeneration. The rapid rise of Reg protein levels to higher levels in the early stages of disease onset is crucial for disease development control and recovery. However, the upregulation of endogenous Reg proteins has a lag of approximately 48 to 72 hours. In addition, the rate of increase in Reg protein expression levels can be significantly reduced with age or increased disease comorbidities. Due to the lack of Reg protein protection, there may be a corresponding delay in inflammatory response, aggravated bacterial infiltration, and increased C-reactive protein levels. The loss of Reg protein protection reduces the patient's ability to resist tissue or organ damage caused by the disease. Therefore, the lack of effective protection of Reg proteins can lead to inflammatory responses and damage to organs and tissues.

[0016] Disclosed herein are stable and effective analogs of the active center of Reg3α. Without wishing to be bound by theory, it is believed that the disclosed compounds can significantly reduce or alleviate the severity of inflammation in the body, and play a beneficial role in reducing or preventing severe systemic inflammatory responses or cytokine storms in COVID-19 patients. The levels of inflammatory cytokines TNF-α, IL-6, and IL-1β (which are the most important inflammatory cytokines involved in inflammatory responses) can be significantly reduced. The disclosed compounds can significantly reduce the infiltration of neutrophils and macrophages, and significantly reduce the severity of damage (including apoptosis and necrosis), thereby helping to prevent or reduce complications and promote recovery, which is of great significance for controlling the disease and improving prognosis.

[0017] In one aspect, the present invention generally relates to a method of treating SARS-CoV-2 infection or a related disease or condition, comprising administering to a subject in need thereof a pharmaceutical composition comprising a peptide that is an analog of the Reg3α active center.

[0018] In another aspect, the present invention generally relates to a method of reducing proinflammatory cytokines comprising administering to a subject in need thereof a pharmaceutical composition comprising a peptide that is an analog of the active site of Reg3α.

[0019] In yet another aspect, the present invention generally relates to a method for treating hypercytokinemia or cytokine storm or a disease or condition involving hypercytokinemia or cytokine storm, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising a peptide that is an analog of the Reg3α active center.

[0020] In certain embodiments, the amino acid sequence of the Reg3α active center is H-IGLHDPSHGTLPNGS-OH.

[0021] In certain embodiments, the Reg3α active site analog is Ac-IGLHDPSHGTLPAGS or a pharmaceutically acceptable form thereof.

[0022] In yet another aspect, the present invention generally relates to a pharmaceutical composition comprising Ac-IGLHDPSHGTLPAGS or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient, carrier or diluent, suitable for treating SARS-CoV-2 infection or related diseases or conditions.

[0023] In yet another aspect, the present invention generally relates to unit dosage forms comprising the pharmaceutical compositions disclosed herein.

[0024] In yet another aspect, the present invention generally relates to the use of Ac-IGLHDPSHGTLPAGS or a pharmaceutically acceptable form thereof for treating SARS-CoV-2 infection or a related disease or condition.

[0025] In yet another aspect, the present invention generally relates to the use of Ac-IGLHDPSHGTLPAGS or a pharmaceutically acceptable form thereof for reducing proinflammatory cytokines or for treating hypercytokinemia or cytokine storm or a disease or disorder involving hypercytokinemia.

[0026] In yet another aspect, the present invention generally relates to the use of Ac-IGLHDPSHGTLPAGS or a pharmaceutically acceptable form thereof for preventing or treating COVID sequelae, or related diseases or conditions.

[0027] In yet another aspect, the present invention generally relates to the use of Ac-IGLHDPSHGTLPAGS or a pharmaceutically acceptable form thereof in the preparation of a medicament for preventing or treating COVID sequelae, or related diseases or conditions. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] FIG. 1 presents exemplary data on the effect of Ac-IGLHDPSHGTLPAGS on survival rate in an LPS-induced mouse model. definition

[0029] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs.The following terms are intended to have the following meanings unless otherwise indicated by the context in which the term appears.

[0030] When a trade name is used herein, unless the context indicates otherwise, the trade name includes product preparations, generic drugs, and active pharmaceutical ingredients of the trade name product.

[0031] The ranges provided herein should be understood as shorthand for all values ​​within the range. For example, a range of 1 to 14 should be understood to include any number, combination of numbers, or sub-range from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14.

[0032] As used herein, "at least" a particular value is to be understood to mean that value and all values ​​greater than that value.

[0033] In this specification and the appended claims, the singular forms "a," "an," and "the," include plural referents unless the context clearly dictates otherwise.

[0034] Unless otherwise specified or obvious from the context, the term "about" as used herein should be understood to be within the normal tolerance range in the art, such as within 2 standard deviations of the mean. Approximately can be understood to be within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05% or 0.01% of the stated value. Unless the context clearly indicates otherwise, all numerical values ​​provided herein can be modified by the term "about".

[0035] Unless otherwise stated or clear from the context, the term "or" as used herein should be understood to be inclusive.

[0036] The term "comprising" when used to define compositions and methods is intended to mean that the compositions and methods include the listed elements, but do not exclude other elements. The term "consisting essentially of" when used to define compositions and methods should mean that the compositions and methods include the listed elements, and exclude other elements that have any substantial significance for the compositions and methods. For example, "consisting essentially of" refers to the use of pharmacologically active agents that are explicitly listed, and excludes pharmacologically active agents that are not explicitly listed. The term "consisting essentially of" does not exclude pharmacologically inactive or inert agents, such as pharmaceutically acceptable excipients, carriers, or diluents. The term "consisting of" when used to define compositions and methods should mean excluding trace elements and substantial method steps of other ingredients. Embodiments defined by each of these transitional terms are within the scope of the present invention.

[0037] As used herein, the term "antibody" refers to a molecule capable of binding an epitope or antigenic determinant. The term is intended to include whole antibodies and antigen-binding fragments thereof. The term encompasses polyclonal, monoclonal, chimeric, Fab, Fv, single-chain antibodies and single or multiple immunoglobulin variable chains or CDR domain designs, as well as bispecific antibodies and multispecific antibodies. Antibodies may be from any animal source. Preferably, the antibody is mammalian, such as human, mouse, rabbit, goat, guinea pig, camel, horse, etc., or other suitable animals. Antibodies may recognize polypeptide or polynucleotide antigens. The term includes active fragments, including, for example, antigen-binding fragments of immunoglobulins, variable and / or constant regions of heavy chains, variable and / or constant regions of light chains, complementary determining regions (cdr) and framework regions. The term includes polyclonal and monoclonal antibody preparations, as well as hybrid antibodies, altered antibodies, chimeric antibodies, hybrid antibody molecules, F(ab) 2 and preparations of F(ab) fragments; Fv molecules (e.g., non-covalent heterodimers), dimer and trimer antibody fragment constructs; minibodies, humanized antibody molecules, and any functional fragments obtained from such molecules, wherein such fragments retain specific binding.

[0038] As used herein, the terms "disease," "disorder," or "condition" are used interchangeably herein to refer to a pathological condition, e.g., one that is identifiable as being a departure from a healthy or normal state by symptoms or other identifying factors. The term "disease" includes disorders, syndromes, conditions, and injuries. Diseases include, but are not limited to, proliferative, inflammatory, immune, metabolic, infectious, and ischemic diseases.

[0039] As used herein, the term "modulate" refers to directly or indirectly producing an increase or decrease, stimulation, inhibition, interference or blocking in the measured activity when compared to an appropriate control. A "modulator" of a polypeptide or polynucleotide refers to a substance that affects (e.g., increases, decreases, stimulates, inhibits, interferes or blocks) the measured activity of a polypeptide or polynucleotide when compared to an appropriate control. For example, a "modulator" can bind to a target with a measurable affinity and / or activate or inhibit a target, or directly or indirectly affect the normal regulation of receptor activity.

[0040] As used herein, the term "pharmaceutically acceptable" excipient, carrier or diluent refers to a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, which is involved in carrying or transporting a subject's agent from one organ or part of the body to another organ or another part of the body. Each carrier must be "acceptable", i.e., compatible with the other ingredients of the formulation and not harmful to the patient. Some examples of materials that can be used as pharmaceutically acceptable carriers include: sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; tragacanth powder; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol; polyols such as glycerol, sorbitol, mannitol, and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethanol; phosphate buffer; and other nontoxic, compatible substances used in pharmaceutical formulations. Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate, magnesium stearate and polyethylene oxide-polypropylene oxide copolymers, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.

[0041] As used herein, "pharmaceutically acceptable forms" of the disclosed compounds include, but are not limited to, pharmaceutically acceptable salts, esters, hydrates, solvates, isomers, prodrugs, and isotopically labeled derivatives of the disclosed compounds. In one embodiment, "pharmaceutically acceptable forms" include, but are not limited to, pharmaceutically acceptable salts, esters, isomers, prodrugs, and isotopically labeled derivatives of the disclosed compounds. In some embodiments, "pharmaceutically acceptable forms" include, but are not limited to, pharmaceutically acceptable salts, esters, stereoisomers, prodrugs, and isotopically labeled derivatives of the disclosed compounds.

[0042] In certain embodiments, the pharmaceutically acceptable form is a pharmaceutically acceptable salt. As used herein, the term "pharmaceutically acceptable salt" refers to salts that are suitable for contact with the tissue of a subject without undue toxicity, irritation, allergic reaction, etc., and are commensurate with a reasonable benefit / risk ratio within the scope of reasonable medical judgment. Pharmaceutically acceptable salts are well known in the art. For example, Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences (1977) Vol. 66: pp. 1-19. Pharmaceutically acceptable salts of the compounds provided herein include salts derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid addition salts are salts formed with inorganic acids (such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid) or organic acids (such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid) to form amino groups, or by using other methods used in the art (such as ion exchange) to form amino groups. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate (besylate), benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like. In some embodiments, organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, lactic acid, trifluoroacetic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.

[0043] These salts can be prepared in situ during the isolation and purification of the disclosed compounds, or separately, such as by reacting the free base or free acid of the parent compound with a suitable base or acid, respectively. Pharmaceutically acceptable salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C 1-4 alkyl) 4Salt. Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, etc. Where appropriate, other pharmaceutically acceptable salts include nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions, such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfonates, and aryl sulfonates. Organic bases from which salts can be derived include, for example, primary amines, secondary amines and tertiary amines, substituted amines (including naturally occurring substituted amines), cyclic amines, basic ion exchange resins, etc., such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine. In some embodiments, pharmaceutically acceptable base addition salts can be selected from ammonium salts, potassium salts, sodium salts, calcium salts, and magnesium salts.

[0044] In certain embodiments, the pharmaceutically acceptable form is a pharmaceutically acceptable ester. As used herein, the term "pharmaceutically acceptable ester" refers to esters that hydrolyze in vivo and includes those esters that are easily decomposed in the human body and leave the parent compound or its salt. Such esters can serve as prodrugs as defined herein. Pharmaceutically acceptable esters include, but are not limited to, alkyl esters, alkenyl esters, alkynyl esters, aryl esters, aralkyl esters, and cycloalkyl esters of acidic groups, including, but not limited to, carboxylic acids, phosphoric acid, phosphinic acid, sulfinic acid, sulfonic acid, and boric acid. Examples of esters include formates, acetates, propionates, butyrates, acrylates, and ethylsuccinates. Esters can be formed by hydroxyl or carboxylic acid groups of the parent compound.

[0045] In certain embodiments, the pharmaceutically acceptable form is a "solvate" (e.g., a hydrate). As used herein, the term "solvate" refers to a compound that also includes a stoichiometric or non-stoichiometric amount of a solvent bound by non-covalent intermolecular forces. The solvate can be a solvate of a disclosed compound or a pharmaceutically acceptable salt thereof. When the solvent is water, the solvate is a "hydrate". Pharmaceutically acceptable solvates and hydrates are complexes that may, for example, include 1 to about 100, or 1 to about 10, or 1 to about 2, about 3, or about 4 solvent molecules or water molecules. It should be understood that the term "compound" as used herein encompasses the compound and solvates of the compound, and mixtures thereof.

[0046] In certain embodiments, the pharmaceutically acceptable form is a prodrug. As used herein, the term "prodrug" (prodrug / pro-drug) refers to a compound that is converted in vivo to produce a pharmaceutically acceptable form of a disclosed compound or the compound. Prodrugs can be inactive when applied to a subject, but can be converted into active compounds in vivo, such as by hydrolysis (e.g., hydrolysis in the blood). In some cases, prodrugs have improved physical and / or delivery properties that are superior to the parent compound. Prodrugs can increase the bioavailability of compounds when applied to subjects (e.g., promote blood absorption after oral administration), or enhance delivery to related biological compartments (e.g., brain or lymphatic system) relative to the parent compound. Exemplary prodrugs include derivatives of disclosed compounds with enhanced water solubility or active transport capability through the intestinal membrane relative to the parent compound.

[0047] Prodrug compounds generally provide advantages of water solubility, tissue compatibility or delayed release in mammalian organisms (see, e.g., Bundgard, H., Design of Prodrugs (1985), Vol. 7-9, pp. 21-24 (Elsevier, Amsterdam). Discussions on prodrugs are presented in Higuchi, T. et al., "Pro-drugs as Novel Delivery Systems", ACSSymposium Series, Vol. 14, and Bioreversible Carriers in Drug Design, Edward B. Roche, ed., American Pharmacists Association and Pergamon Press, 1987, both of which are incorporated herein by reference in their entirety. Exemplary advantages of a prodrug may include, but are not limited to, its physical properties, such as enhanced water solubility when administered parenterally at physiological pH, or it may enhance absorption from the digestive tract, or it may enhance stability of the drug for long-term storage compared to the parent compound.

[0048] As used herein, the term "prevent / preventing / prevention" refers to a method for preventing, delaying, avoiding or stopping the onset, incidence, severity or recurrence of a disease or condition. For example, if the onset, incidence, severity or recurrence of the disease or condition or one or more symptoms thereof in a subject susceptible to the disease or condition is reduced or delayed when compared to a subject not receiving the method, the method is considered to have a preventive effect. After receiving the method, if the onset, incidence, severity or recurrence of one or more symptoms of the disease or condition in a subject susceptible to the disease or condition is reduced or delayed when compared to the progress of the subject before treatment, the disclosed method is also considered to have a preventive effect. The reduction or delay in the onset, incidence, severity or recurrence of osteoporosis can be about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any reduction therebetween.

[0049] Prevention and the like do not mean preventing a subject from developing a particular disease or condition. Prevention may require administration of multiple doses. Prevention may include preventing the recurrence of a disease in a subject in which all disease symptoms have been resolved, or preventing the recurrence of a relapsing-remitting disease.

[0050] As used herein, the terms "subject" and "patient" are used interchangeably herein and refer to a living animal (human or non-human). The subject may be a mammal. The term "mammal" or "mammalian" refers to any animal in the taxonomic classification of mammals. The mammal may be a human or a non-human mammal, such as a dog, cat, pig, cow, sheep, goat, horse, rat, and mouse. The term "subject" does not exclude an individual who is completely normal or normal in all respects with respect to a disease or condition.

[0051] As used herein, the term "treatment" or "treating" a disease or condition refers to a method of reducing, delaying, or ameliorating such a condition or one or more symptoms of such a disease or condition before or after its occurrence. Treatment may involve one or more effects or symptoms of the disease and / or underlying pathology. Treatment may be any degree of alleviation, and may be, but is not limited to, complete elimination of the disease or disease symptoms. Such reduction or prevention may be at least 5%, 10%, 20%, 40%, 50%, 60%, 80%, 90%, 95%, or 100%, as measured by any standard technique, compared to an equivalent untreated control.

[0052] Any composition or method disclosed herein can be combined with one or more of any other compositions and methods provided herein. DETAILED DESCRIPTION

[0053] The present invention provides certain analogs and compositions thereof having a Reg3α active center, which can be effectively used to reduce proinflammatory cytokines and prevent or alleviate cytokine storms in viral infections (e.g., caused by COVID-19), drug treatments or therapies (e.g., during CAR-T therapy), trauma or inflammatory diseases.

[0054] Reg proteins are involved in the growth and differentiation of cells from various organs under normal and disease conditions. They were discovered in the 1970s and 1980s and were named regenerative proteins due to their upregulated expression after organ damage. It is believed to have a role in promoting regeneration. (Terazono et al., 1988, Journal of Biological Chemistry, Vol. 263: pp. 2111–2114; Terazono et al., 1990, Diabetologia., Vol. 33: pp. 250–252.) Subsequently, researchers from different fields named them pancreatitis-associated protein (PAP), pancreatic stone protein (PSP), and hepatocarcinoma-intestinal-pancreatic (HIP) according to their roles in various types of diseases. With the development of protein sequencing technology, it was found that these proteins belonged to the Reg protein family, so they were later collectively referred to as "regenerative proteins" or "Reg proteins." (Parikh et al., 2012, Biomol Concepts., Vol. 3, No. 1: pp. 57-70.) Reg protein is an autocrine stress protein that plays an important protective role when the body is damaged (especially acute and severe body damage), and the expression of Reg protein is significantly upregulated in various inflammatory reactions such as acute pancreatitis, sepsis, peritonitis and acute liver injury, and plays an important protective role in the development and prognosis of the disease. (Reding et al., 2017, Oncotarget., Vol. 8, No. 18: pp. 30162-30174.)

[0055] As early as 1994, clinical trials observed that Reg protein expression increased significantly in all patients on the first day of hospitalization, reaching peak plasma concentrations on the 2nd to 4th day, and then gradually decreased to basal levels. It was observed that the rate of increase in Reg protein expression levels in older patients was significantly slower than that in other patients, indicating that with age, the protective effect of Reg protein may be gradually lost, reducing the patient's ability to resist disease damage. In addition, the study also showed that the rapid rise of Reg protein levels to higher levels in the early stages of the disease is very important for the control and recovery of the disease. (Iovanna et al., 1994, Gastroenterology., Vol. 106, No. 3: pp. 728-734.) These findings were later confirmed in other studies in different disease areas.

[0056] Regenerating islet-derived protein 3 alpha or Reg3α (also known as HIP / PAP (hepatocarcinoma-intestinal-pancreatic / pancreatitis-associated protein) is a protein encoded by the REG3α gene in humans. (Dusetti et al., 1994, Genomics, Vol. 19, No. 1: pp. 108–114.) This gene encodes a pancreatic secretory protein that may be involved in cell proliferation or differentiation. Enhanced expression of this gene is observed during pancreatic inflammation and hepatocarcinogenesis.

[0057] Boeck et al. retrospectively analyzed the Reg protein levels in frozen serum samples from 101 patients clinically diagnosed with ventilator-associated pneumonia (VAP) from the onset to the 7th day to evaluate the correlation between Reg protein levels and organ failure and prognosis (the primary endpoint was death within 28 days after the onset of VAP), thereby evaluating the role of Reg protein in VAP. The results of this study showed that Reg protein levels were well correlated with patient prognosis and could be used as a biomarker associated with organ failure and prognosis in patients with this type of pneumonia. (Boeck et al., 2011, Chest., Vol. 140, No. 4: pp. 925-932.) Scherr et al. also observed a significant increase in Reg protein levels in 200 patients with chronic obstructive pulmonary disease (COPD) caused by bacterial infection, which was directly related to disease severity and mortality. (Scherr et al., 2013, Chest., Vol. 143, No. 2: pp. 379-387.) Qian et al. used ADSC to evaluate the therapeutic effect of adipose-derived stem cells (ADSC) on acute lung injury induced by Staphylococcus aureus in mice. The experimental results showed that intratracheal injection of ADSC reduced the severity of lung inflammation and reduced bacterial load and mortality in infected mice. In addition, experiments have shown that ADSC has a protective and antibacterial effect on lung injury through Reg protein, and further studies have shown that the secretion of Reg protein is mediated by the TLR2-MyD88-JAK2 / STAT3 pathway. (Qian et al., 2016, Stem Cells, Vol. 34, No. 7: pp. 1947-1956.)

[0058] Recent studies have tested whether Reg3α analogs can protect pancreatic acinar cell necrosis and reduce the inflammatory response in acute pancreatitis. The results showed that Reg3α analogs can reduce the severity of acute pancreatitis and have a significant effect in inhibiting systemic inflammatory responses, among which the levels of proinflammatory cytokines TNF-α, IL-6, and IL-1β were significantly reduced. Reg3α analogs significantly reduced the infiltration of neutrophils and macrophages and the severity of damage (including apoptosis and necrosis). Further studies found that Reg3α analogs can downregulate the expression of Toll-like receptor 4 (TLR4) protein, and TLR4 gene knockout in mice prevented Reg3α analogs from playing a beneficial protective role. This proves that Reg3α analogs reduce the severity of inflammation in the body through the TLR4 signaling pathway and further play a significant protective role. (Wu et al., 2019, Biochem Biophys Res Commun., Vol. 512, No. 4: pp. 670-677.)

[0059] Coronaviruses attach to host cells via the trimeric spike S glycoprotein. The host cell's TLR4 recognizes the S protein and leads to the activation of inflammatory cytokines through a MyD88-dependent signal transduction pathway. The interaction between the virus and the cell leads to the massive production of immune mediators. In response to viral infection, infected cells promote the secretion of a large number of inflammatory cytokines (IL-1, IL-6, IL-8, IL-21). These cytokines then recruit lymphocytes and leukocytes to the site of infection.

[0060] In one aspect, the present invention generally relates to a method of reducing proinflammatory cytokines comprising administering to a subject in need thereof a pharmaceutical composition comprising a peptide that is an analog of the active site of Reg3α.

[0061] In another aspect, the present invention generally relates to a method for treating SARS-CoV-2 infection or a related disease or condition, comprising administering to a subject in need thereof a pharmaceutical composition comprising a compound that is a peptide that is an analog of the active center of Reg3α.

[0062] In yet another aspect, the present invention generally relates to a method for treating, alleviating or preventing hypercytokinemia or cytokine storm or a disease or condition involving hypercytokinemia or cytokine storm, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising a peptide that is an analog of the Reg3α active center.

[0063] In yet another aspect, the present invention generally relates to a method for treating, alleviating or preventing inflammatory diseases or conditions involving acute respiratory or pulmonary failure, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising a peptide that is an analog of the Reg3α active center.

[0064] In yet another aspect, the present invention generally relates to a method of treating, alleviating or preventing an inflammatory disease or condition involving acute liver failure, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising a peptide that is an analog of the Reg3α active center.

[0065] In certain embodiments, the amino acid sequence of the Reg3α active center is Ac-H-IGLHDPSHGTLPNGS-OH.

[0066] In certain embodiments, the peptide that is a Reg3α active site analog is Ac-IGLHDPSHGTLPAGS or a pharmaceutically acceptable form thereof.

[0067] In certain embodiments, the subject is ill due to overproduction of immune cells and / or pro-inflammatory cytokines into the subject's lungs.

[0068] In certain embodiments, the subject is ill due to overproduction of immune cells and / or pro-inflammatory cytokines into the subject's liver.

[0069] In certain embodiments, the proinflammatory cytokines include one or more of TNF-α, IL-1, IL-6, IL-12, IFN-α, IFN-β, IFN-γ, MCP-1, IL-8, IL-2, IL-7, IL-18, IL-17, CCL-2, IP-10, MCP-3, and GM-CSF.

[0070] In certain embodiments, the subject suffers from a mild or moderate symptom of a SARS-CoV-2 infection, or a related disease or condition. In certain embodiments, the subject suffers from a severe or critical symptom of a SARS-CoV-2 infection, or a related disease or condition.

[0071] In certain embodiments, the subject suffers from post-COVID sequelae.

[0072] In certain embodiments, the relevant disease or condition is pneumonia and / or lung injury. In certain embodiments, the relevant disease or condition is acute respiratory distress syndrome. In certain embodiments, the relevant disease or condition is systemic inflammatory response syndrome.

[0073] In certain embodiments, the inflammatory disease or disorder is hepatitis. In certain embodiments, the inflammatory disease or disorder is severe hepatitis.

[0074] In certain embodiments, the inflammatory disease or disorder is pneumonia.

[0075] In certain embodiments, the disease or condition treated comprises an inflammatory condition.

[0076] In certain embodiments, the disease or condition treated comprises acute respiratory distress syndrome.

[0077] In certain embodiments, the disease or disorder is a cardiovascular disorder.

[0078] In certain embodiments, the disease or condition of interest is failure of one or more organs.

[0079] In certain embodiments, the at least one organ is selected from the group consisting of lung and liver.

[0080] In certain embodiments, the disease or condition treated is an infection. In certain embodiments, the infection is a viral, bacterial, fungal, or parasitic infection. In certain embodiments, the viral infection is caused by a coronavirus. In certain embodiments, the coronavirus is SARS-CoV-2.

[0081] In certain embodiments, at least 60% of severe SARS-CoV-2 patients with elevated inflammatory factors find that their IL-6 is reduced to normal within 7 days of treatment. In certain embodiments, at least 75% of severe SARS-CoV-2 patients with elevated inflammatory factors find that their IL-6 is reduced to normal within 7 days of treatment. In certain embodiments, at least 85% of severe SARS-CoV-2 patients with elevated inflammatory factors find that their IL-6 is reduced to normal within 7 days of treatment. In certain embodiments, at least 95% of severe SARS-CoV-2 patients with elevated inflammatory factors find that their IL-6 is reduced to normal within 7 days of treatment.

[0082] In certain embodiments, administration of the compound results in preventing or reducing the development of hypercytokinemia in SARS-CoV-2 patients.

[0083] In certain embodiments, the disease or condition is caused by a drug treatment or therapy (e.g., CAR-T therapy).

[0084] In certain embodiments, the disease or condition is trauma.

[0085] In certain embodiments, the administration of the Reg3α active center analog is by subcutaneous administration. In certain embodiments, the administration of the Reg3α active center analog is by intravenous administration. In certain embodiments, the administration of the Reg3α active center analog is by intramuscular administration. In certain embodiments, the administration of the Reg3α active center analog is by inhalation administration.

[0086] Depending on the circumstances, the daily dose may be administered as a single dose or in two or more doses.

[0087] In certain embodiments, the first dose is administered after hypercytokinemia or cytokine storm occurs.

[0088] In certain embodiments, the first dose is administered about 5 minutes to about 1 day (e.g., about 5 minutes to about 12 hours, about 5 minutes to about 3 hours, about 1 minute to about 1 hour) after the onset of hypercytokinemia or cytokine storm.

[0089] In mice, the dosage administered can be in the range of about 2.5 to about 25 mg / kg / day (e.g., about 2.5 to 15 mg / kg / day, about 5 to 10 mg / kg / day, about 5 to 7.5 mg / kg / day), adjusted as appropriate based on patient weight and other considerations.

[0090] With regard to Ac-IGLHDPSHGTLPAGS, in certain embodiments, the compound is administered at a daily dose of about 0.1 mg to about 400 mg (e.g., about 0.1 mg to about 1 mg, about 1 mg to about 5 mg, about 5 mg to about 50 mg, about 50 mg to about 400 mg) for about 1 day to about 14 days (e.g., about 1 day to about 7 days, about 7 days to about 14 days). In certain embodiments, the compound is administered at a daily dose range of about 75 mg to about 300 mg for a period of about 1 day to about 7 days (e.g., 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days). In certain embodiments, the compound is administered at a daily dose range of about 100 mg to about 200 mg for a period of about 1 day to about 7 days (e.g., 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days).

[0091] In certain embodiments, the disclosed methods further comprise administering to the subject a second therapeutic agent.

[0092] In certain embodiments, the second therapeutic agent is a small molecule compound. In certain embodiments, the second therapeutic agent is a small molecule antiviral agent. In certain embodiments, the second therapeutic agent is selected from remdesivir, dexamethasone, hydroxychloroquine, chloroquine, azithromycin, favipiravir, ribavirin and lopinavir.

[0093] In certain embodiments, the second therapeutic agent is an antibody. In certain embodiments, the second therapeutic agent is selected from banivizumab (LY-CoV555), casirumab and idevizumab (REGN-COV2), tocilizumab, salimumab, baricitinib and levitra.

[0094] In certain embodiments, the second therapeutic agent is convalescent plasma.

[0095] In certain embodiments, the second therapeutic agent is PAXLOVID TM (Nimategravir + Ritonavir).

[0096] In certain embodiments, the second therapeutic agent is LAGEVRIO TM (Monupiwe).

[0097] In yet another aspect, the present invention generally relates to a pharmaceutical composition comprising Ac-IGLHDPSHGTLPAGS or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient, carrier or diluent, suitable for treating SARS-CoV-2 infection or related diseases or conditions.

[0098] In another aspect, the present invention generally relates to a pharmaceutical composition comprising Ac-IGLHDPSHGTLPAGS or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient, carrier or diluent, which is suitable for treating, alleviating or preventing hypercytokinemia or cytokine storm or a disease or condition involving hypercytokinemia or cytokine storm.

[0099] In yet another aspect, the present invention generally relates to unit dosage forms comprising the pharmaceutical compositions disclosed herein.

[0100] In certain embodiments, the pharmaceutical composition is an aqueous formulation suitable for subcutaneous injection.

[0101] In certain embodiments, the aqueous formulation is stable at a temperature of about 2°C to about 8°C for at least 48 months.

[0102] In yet another aspect, the present invention generally relates to the use of Ac-IGLHDPSHGTLPAGS or a pharmaceutically acceptable form thereof for treating SARS-CoV-2 infection or a related disease or condition.

[0103] In yet another aspect, the present invention generally relates to the use of Ac-IGLHDPSHGTLPAGS or a pharmaceutically acceptable form thereof for modulating the expression of Toll-like receptor 4 (TLR4) protein.

[0104] In yet another aspect, the present invention generally relates to the use of Ac-IGLHDPSHGTLPAGS or a pharmaceutically acceptable form thereof for reducing proinflammatory cytokines or for treating, reducing or preventing hypercytokinemia or cytokine storm or a disease or condition involving hypercytokinemia.

[0105] In yet another aspect, the present invention generally relates to the use of Ac-IGLHDPSHGTLPAGS or a pharmaceutically acceptable form thereof in the preparation of a medicament for preventing or treating COVID sequelae, or related diseases or conditions. Example

[0106] The following examples are intended to illustrate the practice of the present invention and are not intended to limit it in any way. Effect of Ac-IGLHDPSHGTLPAGS(API) on survival rate in LPS-induced mouse model

[0107] Severe systemic inflammation can be induced in C57BL / 6N mice by lipopolysaccharide (LPS) treatment, peritoneal contamination and infection (PCI), or cecal ligation and puncture (CLP). LPS treatment induces a more robust response than the other treatments. The LPS and PCI models induce a rapid onset of inflammation, including an early increase in serum proinflammatory cytokines and oxidative stress in organ tissues, a rapid decrease in blood glucose values ​​and biotransformation capacity, infiltration of immune cells from the circulation into the liver and spleen, and apoptosis in the spleen. Of all the models tested, LPS had the strongest inflammatory effects. The LPS systemic inflammation model is the most appropriate when studying the effects of new treatments for acute inflammation. Liver function was affected in all three models of systemic inflammation. Materials, Apparatus, and Methods Test product: Ac-IGLHDPSHGTLPAGS (Shenzhen Junshengtai Biotechnology Co., Ltd.) Positive control: dexamethasone (DEX) (Shanghai Biotechnology Co., Ltd.) ·Solvent control: 0.9% NaCl injection (Guizhou Kelun Pharmaceutical Co., Ltd.) Lipopolysaccharide (LPS) (Sigma) Experimental animals

[0108] The male SPF C57BL / 6J mice (6-8 weeks old, weighing approximately 18 g-20 g) used in this study were purchased from Shanghai Slake Laboratory Animal Co., Ltd. The care and use of all animals complied with the 3R principles and relevant regulations. Model building and API application

[0109] One hundred (100) male C57BL / 6J mice (18 g-20 g) were used in the study. After 7 days of acclimatization, a mouse model of inflammation characterized by severe acute systemic inflammatory response was established by a single tail vein injection of LPS (30 mg / kg).

[0110] The model animals were randomly divided into 7 groups: vehicle control group (G0), test group 1 (G1) to test group 5 (G5) and positive control group (G6), with 15 mice / group in G0-G5 and 10 mice / group in G6. Day 1 was defined as the day of tail vein injection of LPS (30 mg / kg), and treatment was carried out for 5 consecutive days from the same day of model establishment (Day 1) to Day 5 (120 hours after LPS induction). The detailed study design is summarized in Table 1 below. Except for the first dose set at 5 minutes before LPS injection, 5 minutes after LPS injection, 1 hour before LPS injection and 1 hour after LPS injection on Day 1 (see the administration schedule in Table 1 for details), each group had the same administration schedule (the second dose was 8 hours after LPS injection, and twice a day in the following days, once in the morning and once in the evening). The vehicle and API were administered by subcutaneous injection in the back, and DEX was administered by gavage. Table 1. Study Design result

[0111] Graphpad 8.0 software was used for data analysis. The survival rate between each treatment group and the vehicle control group was statistically analyzed using the log-rank (Mantel-Cox) test. The results are provided in Table 2 and Figure 1.

[0112] Tremor, lethargy, diarrhea, and mental depression were commonly observed in each group of mice 0-24 hours after LPS injection. Death occurred 16 hours after LPS injection for the vehicle group and 24 hours after LPS injection for the test group. Until 72 hours after LPS injection, a total of 13 mice died in the vehicle group, 1 mouse died in the positive control group, and 9, 6, 8, 11, and 9 mice died in groups G1 to G5, respectively. After 72 hours, no more mice died in any group until the end of the observation at 120 hours.

[0113] Table 2 summarizes the survival rate of each group. Compared with the vehicle control group, the survival rates of the G2, G3, G5 and G6 groups were significantly increased (P < 0.05, P < 0.01). The survival rates of the G1 and G4 groups did not increase significantly (P > 0.05), while the survival rate values ​​of the G1 and G4 groups showed an increasing trend. Table 2. Effect of API on survival in LPS-induced mouse model Note: *P<0.05, **P<0.01, ***P<0.001 compared with the vehicle control group.

[0114] The results showed that API increased the survival rate of mice in LPS-induced death, and test group 3 achieved the most significant beneficial effect, with the survival rate increased to 60% (Figure 1). Clinical study of Ac-IGLHDPSHGTLPAGS (API) in severe COVID-19 patients with elevated inflammatory factors

[0115] A summary of the protocol is provided in Table 3. Table 3. Program Overview Clinical indications, dosage and administration

[0116] The product under investigation is intended for the treatment of patients with severe COVID-19 and elevated inflammatory factors. It is administered by subcutaneous injection. The dose in clinical studies does not exceed 300 mg / day and is not to exceed 7 consecutive days.

[0117] From the perspective of clinical application, considering the expected clinical indications, most patients with COVID-19 and immune responses caused by cytokine storm are acutely seriously infected patients, and oral administration is difficult. In addition, the drug needs to be absorbed quickly to control the progression of the disease. At the same time, small-volume injections also provide convenience for clinical application, which represents a simpler and faster way than powder injections that need to be reconstituted.

[0118] The API is a 15-amino acid peptide. Oral administration may degrade the peptide and fail to achieve the desired effect under existing technologies. Subcutaneous injection is considered to be more advantageous. At the same time, the results of stability studies have shown that the API has good stability and the injection can be safely stored at refrigerated temperatures (2°C-8°C). Preclinical safety data of API

[0119] A series of preclinical studies on API pharmacology and pharmacokinetics were completed in accordance with the ICH guidelines (International Council for Harmonization of Technical Registration of Pharmaceuticals for Human Use), and various preclinical safety evaluations were completed, including safety pharmacology, repeated dosing toxicity, genotoxicity tests, in vitro hemolysis, and in vitro and in vivo allergy tests. In each study, no safety risks related to the API were observed at the maximum administered dose. The no-observed adverse effect level dose (NOAEL) in each trial was the highest dose studied in each study, and the doses planned for clinical trials were 150 mg / day and 300 mg / day, with a safety window of 9.7 to 65.0 times.

[0120] A brief summary of the preclinical safety evaluation of the API is provided in Table 4. Table 4. Summary of preclinical safety studies of API Clinical research of API

[0121] Phase 1 clinical study of API in healthy subjects has been completed. The trial was a randomized, double-blind, placebo-controlled trial conducted by single administration to healthy subjects, involving a total of four dose groups, 8 subjects in each group (6 of whom were given API injections and 2 were given placebos), subcutaneously injected, with doses of 50 mg / day, 100 mg / day, 200 mg / day and 300 mg / day, respectively. The results showed that after subcutaneous injection of API in healthy subjects, it was rapidly absorbed and eliminated, with a median T max 0.5 hours. 4 to 8 hours after administration, the plasma concentration dropped to the limit of quantification, about 2.5 ng / mL. Exposure and peak concentration are proportional to dose. The pharmacokinetic parameters of the API after subcutaneous injection are briefly summarized in Table 5; it was well tolerated at 300 mg / day, and no serious adverse reactions were found at each dose. All adverse reactions were very mild, the most common type being local redness and swelling at the injection site, which had improved or fully recovered by the end of the trial. No individual withdrew from the clinical trial due to dosage reasons. Table 6 summarizes the safety profile. As mentioned above, the API has excellent safety and tolerability in humans. Table 5. Summary of pharmacokinetic parameters following a single subcutaneous injection in healthy adults Notice: AUC inf = Area under the plasma concentration-time curve extrapolated from time zero to infinity; AUC last = the area under the plasma concentration-time curve from time zero to the last measurable concentration moment; C max = maximum plasma concentration; DN = dose normalized; t 1 / 2 = half-life; T max = time to reach maximum concentration a :T max Expressed as median (minimum, maximum). Except T max All parameters except for the above are expressed as mean ± standard error (n, number of subjects). Table 6. Summary of the safety profile following a single subcutaneous administration in healthy adults

[0122] In the formulation research of API, special attention was paid and various effective measures were taken, such as avoiding the use of irritating substances in the finished drug and controlling the pH of the finished drug at the pH of neutral isotonic preparations to reduce irritation at the injection site. These measures effectively reduced irritation at the injection site and were confirmed in the human clinical phase 1 study of API. No individual withdrew from the clinical trial due to administration reasons.

[0123] The data collected from the preclinical safety studies of the API are considered sufficient. Various preclinical safety evaluations have been completed, including safety pharmacology, repeated dosing toxicity, genotoxicity tests, in vitro hemolysis, and in vitro and in vivo allergy tests. In the safety evaluation, no safety risk of the API was observed at the maximum dose of each study. In the Phase 1 clinical human study, after subcutaneous injection of the API in healthy subjects, it was rapidly absorbed and eliminated, and the exposure and peak concentration were proportional to the dose, with good human pharmacokinetic properties. At 300 mg / day, it was well tolerated, no serious adverse reactions were found at each dose, all adverse reactions were very mild, and no individuals withdrew from the clinical trial due to administration reasons. The API has excellent human safety and tolerability. Three similar products of the API have shown good safety and tolerability in patients with different diseases after repeated administration; the INGAP product has been used in humans at a dose of up to 600 mg / day and has only one amino acid composition difference compared with the API. During the course of continuous administration for 90 days, the safety and tolerability of INGAP were good, which supports the safety and tolerability of the API during repeated administration to humans. APIs and finished drugs for clinical trials

[0124] The API finished drug studied is a small-volume injection of 100 mg / mL. The API injection is prepared using a conventional injection preparation process. The process steps include: dissolution, pH adjustment, filtration, filling, labeling and packaging, and delivery. The excipients used are conventional pharmaceutical excipients, namely sodium acetate, sodium hydroxide, sodium chloride, and water for injection. One non-GMP batch and one GMP batch of API injection solution have been produced. The product quality control standards are formulated in accordance with the relevant regulations and requirements of ICHQ6A and combined with its process and product characteristics; the quality control standards include appearance, pH value, filling volume, osmotic pressure, insoluble particles, characteristics, content, related substances, sterility, and bacterial endotoxins. The quality control analytical methods are established based on the pharmacopoeial methods or developed by the applicant. All methods developed by the company are established in accordance with the ICH guidelines and have completed the necessary methodological validation to ensure the stability and reliability of the methods.

[0125] The stability results of existing GMP batches showed that all test indicators of the API injection met the quality control standards after 48 months under long-term storage conditions at 2°C-8°C.

[0126] A summary of the protocol for the clinical study is provided in Table 3. It should be noted that the clinical trial protocols disclosed herein may be modified, for example, for compliance and consultation with regulatory agencies.

[0127] Applicant's disclosure is described herein with reference to the accompanying drawings in preferred embodiments, wherein like numerals represent identical or similar elements. References throughout the specification to "one embodiment" or "an embodiment" or similar language mean that a particular feature, structure, or characteristic described in conjunction with the embodiment is included in at least one embodiment of the present invention. Thus, phrases "in one embodiment," "in an embodiment," and similar language appearing throughout the specification may, but do not necessarily, all refer to the same embodiment.

[0128] The features, structures or characteristics of the applicant's disclosure may be combined in one or more embodiments in any suitable manner. In the description herein, many specific details are described to provide a thorough understanding of the embodiments of the present invention. However, those skilled in the relevant art will recognize that the applicant's compositions and / or methods may be practiced without one or more specific details, or practiced with other methods, components, materials, etc. In other cases, well-known structures, materials or operations are not shown or described in detail to avoid blurring aspects of the present disclosure.

[0129] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those of ordinary skill in the art. Although any methods and materials similar or equivalent to the methods and materials described herein can also be used in the practice or testing of the present disclosure, preferred methods and materials are currently described. The methods described herein can be performed in any order that is logically possible, except for the specific order disclosed. Reference Merge

[0130] References and citations to other documents, such as patents, patent applications, patent publications, periodicals, books, papers, web content are incorporated throughout this disclosure. All of these documents are hereby incorporated by reference in their entirety for all purposes. Any material or portion thereof that is considered to be incorporated by reference herein but conflicts with existing definitions, statements, or other public materials clearly set forth herein is incorporated only to the extent that no conflict occurs between the incorporated material and the present disclosure. In the event of a conflict, the conflict will be resolved in a manner that is favorable to the present disclosure as a preferred disclosure. Principle of Equivalence

[0131] The representative examples are intended to help illustrate the present invention and are not intended to, and should not be construed as, limiting the scope of the present invention. Indeed, various modifications of the present invention and many other embodiments thereof, in addition to those shown and described herein, will become apparent to those skilled in the art in light of the entire contents of this document, including the examples included herein and references to scientific and patent literature. The examples contain important additional information, illustrations, and guidance that may be suitable for the practice of the present invention in its various embodiments and their equivalents.

Claims

1. A method for treating SARS-CoV-2 infection or related diseases or conditions, comprising administering a pharmaceutical composition to a subject in need thereof, wherein the pharmaceutical composition comprises a compound of a Reg3α active center analog.

2. The method of claim 1, wherein the compound is Ac-IGLHDPSHGTLPAGS or a pharmaceutically acceptable form thereof.

3. The method of claim 1 or 2, wherein the subject has mild or moderate symptoms of SARS-CoV-2 infection, or a related disease or condition.

4. The method of claim 1 or 2, wherein the subject suffers from a severe or critical condition of SARS-CoV-2 infection, or a related disease or condition.

5. The method according to any one of claims 1 to 4, wherein the relevant disease or condition is pneumonia and / or lung injury.

6. The method according to any one of claims 1 to 4, wherein the associated disease or condition is acute respiratory distress syndrome.

7. The method according to any one of claims 1 to 4, wherein the associated disease or condition is systemic inflammatory response syndrome.

8. The method according to any one of claims 1 to 4, wherein the associated disease or condition is cytokine storm.

9. The method according to any one of claims 1 to 4, wherein the relevant disease or disorder is a cardiovascular disorder.

10. The method according to any one of claims 1 to 4, wherein the associated disease or condition is failure of one or more organs.

11. The method according to any one of claims 1 to 4, wherein the associated disease or condition is lung failure.

12. The method according to any one of claims 1 to 4, wherein the associated disease or condition is liver failure.

13. The method of any one of claims 1 to 4, wherein the associated disease or condition is post-COVID syndrome.

14. A method for treating, alleviating or preventing hypercytokinemia or cytokine storm or a disease or condition involving hypercytokinemia or cytokine storm, the method comprising administering a pharmaceutical composition comprising a compound that is an analog of the Reg3α active center to a subject in need thereof.

15. The method of claim 14, wherein the compound is Ac-IGLHDPSHGTLPAGS or a pharmaceutically acceptable form thereof.

16. The method of claim 14 or 15, wherein the subject is ill due to overproduction of immune cells and / or pro-inflammatory cytokines into the subject's lungs.

17. The method of claim 16, wherein the proinflammatory cytokines include one or more of TNF-α, IL-1, IL-6, IL-12, IFN-α, IFN-β, IFN-γ, MCP-1, IL-8, IL-2, IL-7, IL-18, IL-17, CCL-2, IP-10, MCP-3, and GM-CSF.

18. The method of any one of claims 14 to 17, wherein the disease or disorder is an inflammatory disorder.

19. The method of any one of claims 14 to 17, wherein the disease or condition is an infection.

20. The method of claim 19, wherein the infection is a viral, bacterial, fungal or parasitic infection.

21. The method of claim 20, wherein the viral infection is caused by a coronavirus.

22. The method of claim 21, wherein the coronavirus is SARS-CoV-2.

23. The method of claim 22, wherein at least 60% of severe SARS-CoV-2 patients with elevated inflammatory factors are found to have their IL-6 reduced to normal within 7 days of treatment.

24. The method of any one of claims 14 to 23, wherein administration of the compound results in preventing or reducing the development of hypercytokinemia in SARS-CoV-2 patients.

25. The method of any one of claims 14 to 17, wherein the disease or condition is failure of one or more organs.

26. The method of claim 25, wherein the associated disease or condition is lung failure.

27. The method of claim 25, wherein the associated disease or condition is liver failure.

28. The method of any one of claims 14 to 17, wherein the disease or condition is due to a drug treatment or therapy.

29. The method of any one of claims 11 to 17, wherein the drug treatment or therapy is CAR-T therapy.

30. The method of any one of claims 11 to 17, wherein the disease or condition is trauma.

31. The method according to any one of claims 1 to 30, wherein the administration is subcutaneous, intravenous, intramuscular or by inhalation.

32. The method of claim 31, wherein the administration is subcutaneous injection.

33. The method of claim 31 or 32, wherein the compound is administered at a daily dose ranging from about 0.1 mg to about 400 mg for a period of about 1 day to about 14 days.

34. The method of claim 33, wherein the compound is administered at a daily dose ranging from about 75 mg to about 300 mg for a period of about 1 day to about 7 days.

35. The method of claim 34, wherein the compound is administered at a daily dose ranging from about 100 mg to about 200 mg for a period of about 1 day to about 7 days.

36. The method of any one of claims 1 to 35, further comprising administering to the subject a second therapeutic agent.

37. The method of claim 36, wherein the second therapeutic agent is a small molecule compound.

38. The method of claim 37, wherein the second therapeutic agent is a small molecule antiviral agent.

39. The method of claim 37, wherein the second therapeutic agent is selected from remdesivir, dexamethasone, hydroxychloroquine, chloroquine, azithromycin, favipiravir, ribavirin, and lopinavir.

40. The method of claim 36, wherein the second therapeutic agent is an antibody.

41. The method of claim 40, wherein the second therapeutic agent is selected from the group consisting of banivizumab (LY-CoV555), casirizumab and idevizumab (REGN-COV2), tocilizumab, salimumab, baricitinib, and lenvizumab.

42. The method of claim 36, wherein the second therapeutic agent is convalescent plasma.

43. A pharmaceutical composition comprising Ac-IGLHDPSHGTLPAGS or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient, carrier or diluent, suitable for treating SARS-CoV-2 infection or related diseases or conditions.

44. A unit dosage form comprising the pharmaceutical composition according to claim 43.

45. The unit dosage form according to claim 44, wherein the pharmaceutical composition is an aqueous formulation suitable for subcutaneous injection.

46. ​​The unit dosage form according to claim 45, wherein said aqueous formulation is stable at a temperature of about 2°C to about 8°C for at least 48 months.

47. Use of Ac-IGLHDPSHGTLPAGS or a pharmaceutically acceptable form thereof for treating SARS-CoV-2 infection or related diseases or conditions.

48. Use of Ac-IGLHDPSHGTLPAGS or a pharmaceutically acceptable form thereof for preventing or treating COVID sequelae, or related diseases or conditions.

49. Use of Ac-IGLHDPSHGTLPAGS or a pharmaceutically acceptable form thereof for treating, alleviating or preventing hypercytokinemia or cytokine storm or a disease or disorder involving hypercytokinemia or cytokine storm.

50. Use of Ac-IGLHDPSHGTLPAGS or a pharmaceutically acceptable form thereof in the preparation of a medicament for treating SARS-CoV-2 infection or related diseases or conditions.

51. Use of Ac-IGLHDPSHGTLPAGS or a pharmaceutically acceptable form thereof in the preparation of a medicament for preventing or treating COVID sequelae or related diseases or conditions.